Teva Pharmaceutical Industries (NYSE: TEVA – Get a rating) and Avid Bioservices (NASDAQ: CDMO – Get a rating) are both medical companies, but which is the higher value? We’ll compare the two companies based on the strength of their profitability, risk, valuation, earnings, institutional ownership, analyst recommendations and dividends.
This table compares the net margins, return on equity and return on assets of Teva Pharmaceutical Industries and Avid Bioservices.
|Net margins||Return on equity||return on assets|
|Teva Pharmaceutical Industries||2.63%||24.40%||5.67%|
This is a breakdown of recent valuations and price targets for Teva Pharmaceutical Industries and Avid Bioservices, as provided by MarketBeat.com.
|Sales Ratings||Hold odds||Buy reviews||Strong buy odds||Rating|
|Teva Pharmaceutical Industries||0||4||2||0||2.33|
Teva Pharmaceutical Industries currently has a consensus price target of $12.00, indicating a potential upside of 18.69%. Avid Bioservices has a consensus price target of $29.50, indicating a potential upside of 65.73%. Given Avid Bioservices’ higher consensus rating and higher upside potential, analysts clearly think Avid Bioservices is more favorable than Teva Pharmaceutical Industries.
Institutional and Insider Ownership
47.6% of Teva Pharmaceutical Industries shares are held by institutional investors. By comparison, 87.8% of Avid Bioservices’ shares are held by institutional investors. 0.7% of the shares of Teva Pharmaceutical Industries are held by insiders of the company. By comparison, 1.5% of Avid Bioservices’ stock is held by company insiders. Strong institutional ownership indicates that hedge funds, endowments, and large fund managers believe a stock will outperform the market over the long term.
Benefits and evaluation
This table compares the revenue, earnings per share and valuation of Teva Pharmaceutical Industries and Avid Bioservices.
|Gross revenue||Price/sales ratio||Net revenue||Earnings per share||Price/earnings ratio|
|Teva Pharmaceutical Industries||$15.88 billion||0.70||$417.00 million||$0.38||26.61|
|Avid Bioservices||$95.87 million||11:46||$11.21 million||$0.16||111.26|
Teva Pharmaceutical Industries has higher revenues and profits than Avid Bioservices. Teva Pharmaceutical Industries trades at a lower price-to-earnings ratio than Avid Bioservices, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Teva Pharmaceutical Industries has a beta of 1.22, which means its stock price is 22% more volatile than the S&P 500. In comparison, Avid Bioservices has a beta of 2.18, which means its stock price is 118% more volatile than the S&P 500.
Avid Bioservices beats Teva Pharmaceutical Industries on 10 out of 14 factors compared between the two stocks.
Teva Pharmaceutical Industries Company Profile (Get a rating)
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets and distributes generic drugs, specialty drugs and biopharmaceuticals in North America, Europe and internationally. The company offers sterile products, hormones, high potency drugs and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments and creams. It also develops, manufactures and sells active pharmaceutical ingredients. Additionally, he focuses on the central nervous system, pain, respiratory, and oncology. Its central nervous system products include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease. The Company’s products in the respiratory market include ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease . Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a MedinCell collaboration for the development and commercialization of several long-acting injectable products, a suspension of risperidone for the treatment of patients with schizophrenia. The company was founded in 1901 and is based in Tel Aviv-Yafo, Israel.
Avid Bioservices Company Profile (Get a rating)
Avid Bioservices, Inc., a contract development and manufacturing organization, provides clinical and commercial process development and Current Good Manufacturing Practices (CGMP) services focused on mammalian cell culture-derived biopharmaceutical drug substances . It produces monoclonal antibodies and recombinant proteins; and offers services including clinical and commercial CGMP drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. The Company also provides various process development services, such as upstream and downstream development and optimization, analytical method development, testing and characterization. It serves biotechnology and pharmaceutical companies. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California.
Get news and reviews for Teva Pharmaceutical Industries Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com’s FREE daily newsletter.